Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) EBT: 2016-2024

Historic EBT for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to -$422.7 million.

  • Denali Therapeutics' EBT rose 3.98% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year increase of 3.57%. This contributed to the annual value of -$422.7 million for FY2024, which is 191.13% down from last year.
  • As of FY2024, Denali Therapeutics' EBT stood at -$422.7 million, which was down 191.13% from -$145.2 million recorded in FY2023.
  • In the past 5 years, Denali Therapeutics' EBT ranged from a high of $72.0 million in FY2020 and a low of -$422.7 million during FY2024.
  • For the 3-year period, Denali Therapeutics' EBT averaged around -$298.0 million, with its median value being -$326.0 million (2022).
  • In the last 5 years, Denali Therapeutics' EBT soared by 136.35% in 2020 and then tumbled by 504.61% in 2021.
  • Yearly analysis of 5 years shows Denali Therapeutics' EBT stood at $72.0 million in 2020, then tumbled by 504.61% to -$291.2 million in 2021, then dropped by 11.96% to -$326.0 million in 2022, then soared by 55.46% to -$145.2 million in 2023, then slumped by 191.13% to -$422.7 million in 2024.